Skip to main content
Log in

NSAID-Induced Nephrotoxicity from the Fetus to the Child

  • Review Article
  • Published:
Drug Safety Aims and scope Submit manuscript

Abstract

In this review we report data available from the literature on the use of nonsteroidal anti-inflammatory drugs (NSAIDs) and the development of nephrotoxicity in the fetus, neonates and children. Up to the present day, several cases of severe and sometimes irreversible renal insufficiency have been described in neonates exposed to indomethacin prenatally or in the first days of life for treatment of patent ductus arteriosus (PDA). Until now, very few studies have been carried out on alternative treatments for PDA in preterm infants; ibuprofen has been shown to be as effective as indomethacin in closing the ductus in this patient group without affecting renal function. In children, NSAID-induced renal failure is a rare event and is usually reversible after discontinuation of the drug. However, caution should be taken when NSAIDs are administered to individuals with preexisting renal problems or with other potentially nephrotoxic drugs. In these situations, new approaches such as cyclo-oxygenase-2 selective inhibitors or prostanoid receptor selective antagonists could lead to alternative therapies for use in paediatrics.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Table II
Table I

Similar content being viewed by others

References

  1. Kennedy L. NSAIDs and their effect on renal function. Pediatr Adolesc Med Alert 1999; 1(6): 41–8

    Google Scholar 

  2. Garella S. Drug-induced renal disease. Hosp Pract 1993; 15: 129–40

    Google Scholar 

  3. Clive DM, Stoff JS. Renal syndromes associated with nonsteroidal antiinflammatory drugs. N Engl J Med 1984; 310: 563–72

    Article  PubMed  CAS  Google Scholar 

  4. Murray MD, Brater DC. Adverse effects of nonsteroidal antiinflammatory drugs on renal function. Ann Intern Med 1990; 112: 559–60

    PubMed  CAS  Google Scholar 

  5. Dubose TD. Grand round: nephrotoxicity of non-steroidal antiinflammatory drugs. Lancet 1994; 344: 515–8

    Article  Google Scholar 

  6. Schlondorff D. Renal complications of non-steroidal drugs. Kidney Int 1993; 44: 643–53

    Article  PubMed  CAS  Google Scholar 

  7. Bennett W, Henrich W, Stoff JS. The renal effects of nonsteroidal antiinflammatory drugs. Summary and recommendations. Am J Kidney Dis 1996; 26: S56–62

    Article  Google Scholar 

  8. Smith W. Prostanoid biosynthesis and mechanism of action.Am J Physiol 1992; 263: F181–91

    PubMed  CAS  Google Scholar 

  9. Narumiya S, Sugimoto Y, Ushikubi F. Prostanoid receptors: structures, properties and functions. Physiol Rev 1999; 79: 1193–226

    PubMed  CAS  Google Scholar 

  10. Palmer BF. Renal complications associated with the use of nonsteroidal anti-inflammatory agents. J Invest Med 1995; 43: 516–33

    CAS  Google Scholar 

  11. Kaplan BS, Restaino I, Raval DS, et al. Renal failure in the neonate associated with in utero exposure to non-steroidal anti-inflammatory agents. Pediatr Nephrol 1994; 8(6): 700–4

    Article  PubMed  CAS  Google Scholar 

  12. Crofford LJ. COX-1 and COX-2 tissue expression: implications and predictions. J Rheumatol 1997; 49: 15–9

    CAS  Google Scholar 

  13. Guan Y, Chang M, Cho W, et al. Cloning, expression and regulation of rabbit cyclooxygenase-2 in renal medullary interstitial cells. Am J Physiol 1997; 273: F18–26

    PubMed  CAS  Google Scholar 

  14. Kömhoff M, Gröne H, Klein T, et al. Localization of cyclooxygenase-1 and −2 in adult and fetal human kidney: implication for renal function. Am J Physiol 1997; 272: F460–8

    PubMed  Google Scholar 

  15. Slater D, Dennes W, Sawdy R, et al. Expression of cyclooxygenase types-1 and −2 in human fetalmembranes throughout pregnancy. J Mol Endocrinol 1999; 22: 125–30

    Article  PubMed  CAS  Google Scholar 

  16. Sawdy R, Slater D, Fisk N, et al. Use of a cyclo-oxygenase type-2-selective non-steroidal anti-inflammatory agent to prevent preterm delivery. Lancet 1997; 350: 265–6

    Article  PubMed  CAS  Google Scholar 

  17. Guerguerian AM, Hardy P, Bhattacharya M, et al. Expression of cyclooxygenases in ductus arteriosus of fetal and newborn pigs. Am J Obstet Gynecol 1998; 179: 1618–26

    Article  PubMed  CAS  Google Scholar 

  18. Clyman RI, Chan CY, Mauray F, et al. Permanent anatomic closure of the ductus arteriosus in newborn baboons: the roles of postnatal constriction, hypoxia and gestation. Pediatr Res 1999; 45: 19–29

    Article  PubMed  CAS  Google Scholar 

  19. Clyman RI, Hardy P, Waleh N, et al. Cyclooxygenase-2 plays a significant role in regulating the tone of the fetal lamb ductus arteriosus. Am J Physiol 1999; 276: R913–21

    PubMed  CAS  Google Scholar 

  20. Breyer MD, Breyer RM. Prostaglandin receptors: their role in regulating renal function. Curr Opin Nephrol Hypertens 2000; 9: 23–9

    Article  PubMed  CAS  Google Scholar 

  21. Boye Y, Stocco R, Sawyer N, et al. Molecular cloning and characterization of the four rat prostaglandin E2 prostanoid receptor subtypes. Eur J Pharmacol 1997; 340: 227–41

    Article  Google Scholar 

  22. Ishibashi R, Tanaka I, Kotani M, et al. Roles of prostaglandin E receptors in mesangial cells under high-glucose conditions. Kidney Int 1999; 56: 589–600

    Article  PubMed  CAS  Google Scholar 

  23. Regan JW, Bailey TJ, Pepperl DJ, et al. Cloning of a novel human prostaglandin receptor with characteristics of the pharmacologically defined EP2 subtype. Mol Pharmacol 1994; 46: 213–20

    PubMed  CAS  Google Scholar 

  24. Coleman RA, Smith WL, Narumiya S. International union of pharmacology classification of prostanoid receptors: properties, distribution and structure of the receptors and their subtypes. Pharmacol Rev 1994; 46: 205–29

    PubMed  CAS  Google Scholar 

  25. Segi E, Sugimoto Y, Yamasaki A, et al. Patent ductus arteriosus and neonatal death in prostaglandin receptor EP4-deficient mice. Biochem Biophys Res Commun 1998; 246: 7–12

    Article  PubMed  CAS  Google Scholar 

  26. Bolger PM, Einser GM, Ramwell PW, et al. Renal action of prostacyclin. Nature 1978; 271: 467–9

    Article  PubMed  CAS  Google Scholar 

  27. Bugge JF, Stokke ES, Vikse A, et al. Stimulation of renin release by PGE2 and PGI2 infusion in the dog: enhancing effect of ureteral occlusion or administration of ethacrynic acid. Acta Physiol Scand 1990; 138: 193–201

    Article  PubMed  CAS  Google Scholar 

  28. Wilkes M, Solomon J, Maita M, et al. Characterization of glomerular thromboxane receptor sites in the rat. Am J Physiol 1989; 256: F1111–6

    PubMed  CAS  Google Scholar 

  29. Moise KJ, Huhta JC, Sharif DS, et al. Indomethacin in the treatment of premature labor. N Engl J Med 1988; 319: 327–31

    Article  PubMed  Google Scholar 

  30. Mamapoulos M, Assimakopoulos E, Reece EA, et al. Maternal indomethacin therapy in the treatment of polyhydramnios. Am J Obstet Gynecol 1990; 162: 1225–9

    Google Scholar 

  31. Moise KJ. Effect of advancing gestational age on the frequency of fetal ductal constriction in association with maternal indomethacin use. Am J Obstet Gynecol 1993; 168: 1350–3

    PubMed  Google Scholar 

  32. Gleason CA. Prostaglandins and the developing kidney. Semin Perinatol 1987; 11: 12–21

    PubMed  CAS  Google Scholar 

  33. Dudley DKL, Hardie MC. Fetal and neonatal effects of indomethacin used as a tocolytic agent. Am J Obstet Gynecol 1985; 151: 181–4

    PubMed  CAS  Google Scholar 

  34. Niebyl JR, Witter FR. Neonatal outcome after indomethacin treatment for preterm labor. Am J Obstet Gynecol 1986; 155: 747–9

    PubMed  CAS  Google Scholar 

  35. Morales WJ, Smith SG, Angel JL, et al. ai]Efficacy and safety of indomethacin versus ritodine in the management of preterm labor: a randomized study. Obstet Gynecol 1989; 74: 567–72

    PubMed  CAS  Google Scholar 

  36. Wurtzel D. Prenatal administration of indomethacin as a tocolytic agent: effect on neonatal renal function. Obstet Gynecol 1990; 76: 689–92

    PubMed  CAS  Google Scholar 

  37. Itskovitz J, Abramovi H, Brandes JM. Oligohydramnios, meconium and perinatal death concurrent with indomethacin treatment in human pregnancy. J Reprod Med 1980; 24: 137–40

    PubMed  CAS  Google Scholar 

  38. Jacqz-Aigrin E, Guillonneau M, Boissinot C, et al. Effets maternels et néonatals de l’indomethacine administrée pendant la grossesse. Arch Fr Pediatr 1993; 50: 307–12

    Google Scholar 

  39. Norton ME, Merrill J, Cooper BA, et al. Neonatal complications after the administration of indomethacin for preterm labor. N Engl J Med 1993; 329: 1602–7

    Article  PubMed  CAS  Google Scholar 

  40. Panter KR, Hannah ME, Amankwah KS, et al. The effect of indomethacin tocolysis in preterm labour on perinatal outcome: a randomized placebo-controlled trial. Br J Obstet Gynecol 1999; 106: 467–73

    Article  CAS  Google Scholar 

  41. Pomeranz A, Korzets Z, Dolfin Z, et al. Acute renal failure in the neonate induced by the administration of indomethacin as a tocolytic agent. Nephrol Dial Transplant 1996; 11: 1139–41

    Article  PubMed  CAS  Google Scholar 

  42. Restaino I, Kaplan BS, Kaplan P, et al. Renal dysgenesis in a monozygotic twin: association with in utero exposure to indomethacin. Am J Med Genet 1991; 39: 252–7

    Article  PubMed  CAS  Google Scholar 

  43. Simeoni U, Messer J, Weisburd P, et al. Neonatal renal dysfunction and intrauterine exposure to prostaglandin synthesis inhibitors. Eur J Pediatr 1989; 148: 371–3

    Article  PubMed  CAS  Google Scholar 

  44. Souter D, Harding J, McCowal L, et al. Antenatal indomethacin — adverse fetal effects confirmed. Aust NZ J Obstet Gynecol 1998; 38: 11–6

    Article  CAS  Google Scholar 

  45. Van der Heijden BJ, Carlus C, Narcy F, et al. Persistent anuria, neonatal death and renal microcystic lesions after prenatal exposure to indomethacin. Am J Obstet Gynecol 1994; 171 (3): 617–23

    PubMed  Google Scholar 

  46. Veersema D, De Jong PA, Van Wijck JAM. Indomethacin and the fetal renal non function syndrome. Eur J Obstet Gynecol Reprod Biol 1983; 16: 113–21

    Article  PubMed  CAS  Google Scholar 

  47. Clyman RI. Medical treatment of patent ductus arteriosus in premature infants. In: Long WA, editor. Fetal and neonatal cardiology. Philadelphia: WB Saunders, 1990: 682–90

    Google Scholar 

  48. Cotton RB, Stahlman MT, Bender HW, et al. Randomized trial of early closure of symptomatic patent ductus arteriosus. J Pediatr 1978; 93: 647–51

    Article  PubMed  CAS  Google Scholar 

  49. Stefano JL, Abbasi S, Pearlman SA, et al. Closure of the ductus arteriosus with indomethacin in ventilated neonates with respiratory distress syndrome: effects on pulmonary compliance and ventilation. Am Rev Respir Dis 1991; 143: 236–9

    PubMed  CAS  Google Scholar 

  50. Van Overmeire B, Follens I, Hartmann S, et al. Treatment of patent ductus arteriosus with ibuprofen. Arch Dis Child 1997; 76(3): 179–84

    Google Scholar 

  51. Aranda JV, Varvarigou N, Beharri K, et al. Pharmacokinetics and protein binding of intravenous ibuprofen in the premature newborn infants. Acta Pediatr 1997; 86(3): 289–93

    Article  CAS  Google Scholar 

  52. Betkerur MV, Yeh TF, Miller K, et al. Indomethacin and its effect on renal function and urinary kallikrein excretion in premature infants with patent ductus arteriosus; Pediatrics 1981; 68: 99–102

    PubMed  CAS  Google Scholar 

  53. Kuo CY. Treatment of patent ductus arteriosus with low-dose indomethacin in very low birth weight neonates with impairment of renal function: report of three cases. J Perinatol Med 1996; 24(6): 657–60

    Article  CAS  Google Scholar 

  54. Lin YJ, Tsai YJ, Chen JS, et al. Renal effects and urinary excretion of prostaglandin following indomethacin therapy in premature infants with patent ductus arteriosus. Acta Pediatr Sin 1995; 36: 104–7

    CAS  Google Scholar 

  55. Ment LR, Oh W, Ehrenkranz RA, et al. Low dose indomethacin and prevention of intraventricular hemorrhage: a multicenter randomized trial. Pediatrics 1994; 93: 543–50

    PubMed  CAS  Google Scholar 

  56. Mosca F, Bray M, Lattanzio M, et al. Comparative evaluation of the effects of indomethacin and ibuprofen on cerebral perfusion and oxygenation in preterm infants with patent ductus arteriosus. J Pediatr 1997; 131(4): 549–54

    Article  PubMed  CAS  Google Scholar 

  57. Ng PC, So KW, Fok TF, et al. Comparing sulindac with indomethacin for closure of ductus arteriosus in preterm infants. J Pediatr Child Health 1997; 33(4): 324–8

    Article  CAS  Google Scholar 

  58. Patel J, Marks KA, Roberts I, et al. Ibuprofen treatment of patent ductus arteriosus. Lancet 1995; 346: 255

    Article  PubMed  CAS  Google Scholar 

  59. Rennie JM, Doyle J, Cooke RWI. Early administration of indomethacin to preterm infants. Arch Dis Child 1986; 61: 233–8

    Article  PubMed  CAS  Google Scholar 

  60. Van Bel F, Guit GL, Schipper J, et al. Indomethacin-induced changes in renal blood flow velocity waveform in premature infants investigated with color Doppler imaging. J Pediatr 1991; 118: 621–6

    Article  PubMed  Google Scholar 

  61. Van Overmeire B, Brus F, Van Acker KJ, et al. Aspirin versus indomethacin treatment of patent ductus arteriosus in preterm infants with respiratory distress syndrome. Pediatr Res 1995; 38(6): 886–91

    Article  PubMed  Google Scholar 

  62. Varvarigou A, Bardin CL, Beharry K, et al. Early ibuprofen administration to prevent patent ductus arteriosus in premature newborn infants. JAMA 1996; 275(7): 539–44

    Article  PubMed  CAS  Google Scholar 

  63. Yeh TF, Luken JA, Thaliji A, et al. Intravenous indomethacin therapy in premature infants with persistent ductus arteriosus: a double-blind controlled study. J Pediatr 1981; 98: 137–45

    Article  PubMed  CAS  Google Scholar 

  64. Merritt TA, Harris JP, Roghmann K, et al. Early closure of the patent ductus arteriosus in very low birth weight infants: a controlled trial. J Pediatr 1981; 99: 281–6

    Article  PubMed  CAS  Google Scholar 

  65. Gersony WM, Peckham GJ, Ellison CR, et al. Effects of indomethacin in premature infants with patent ductus arteriosus: results of a national collaborative study. J Pediatr 1983; 102: 895–906

    Article  PubMed  CAS  Google Scholar 

  66. Mahony L, Carnero V, Brett C, et al. Prophylactic indomethacin therapy for patent ductus arteriosus in very-low-birth-weight infants. N Engl J Med 1982; 306: 506–10

    Article  PubMed  CAS  Google Scholar 

  67. Cotton RB, Haywood JL, Fitzgerald GA. Symptomatic patent ductus arteriosus following prophylactic indomethacin. Biol Neonate 1991; 60: 273–82

    Article  PubMed  CAS  Google Scholar 

  68. Krueger E, Mellander M, Bratton D, et al. Prevention of symptomatic patent ductus arteriosus with a single dose of indomethacin. J Pediatr 1987; 111: 749–54

    Article  PubMed  CAS  Google Scholar 

  69. Laudignon N, Chemtob S, Bard H, et al. Effect of indomethacin on the cerebral blood flow velocity of premature newborns. Biol Neonate 1988; 54: 254–62

    Article  PubMed  CAS  Google Scholar 

  70. Yeh TF, Wilks A, Singh J, et al. Furosemide prevents renal side-effects of indomethacin therapy in preterm infants with persistent ductus arteriosus. J Pediatr 1982; 101: 433–7

    Article  PubMed  CAS  Google Scholar 

  71. Rennie JM, Cooke RWI. Prolonged low dose indomethacin for persistent ductus arteriosus of prematurity. Arch Dis Child 1991; 66: 55–8

    Article  PubMed  CAS  Google Scholar 

  72. Hammerman C, Aramburo MJ. Prolonged indomethacin therapy for the prevention of recurrences of patent ductus arteriosus. J Pediatr 1990; 117: 771–6

    Article  PubMed  CAS  Google Scholar 

  73. Fajardo CA, Whyte RK, Steele BT. Effect of dopamine on failure of indomethacin to close the patent ductus arteriosus. J Pediatr 1992; 121: 771–5

    Article  PubMed  CAS  Google Scholar 

  74. Fujiwara T. Closure of PDA with mefenamic acid. In: Robertson B, Van Golde LMG, editors. Pulmonary surfactant. Amsterdam: Elsevier Science Publishers, 1984: 495

  75. Sakhalkar VS, Merchant RH. Therapy of symptomatic patent ductus arteriosus in preterms using mefenamic acid and indomethacin. Indian Pediatr 1992; 29: 313–8

    PubMed  CAS  Google Scholar 

  76. Coceani F, White E, Bodach E, et al. Age-dependent changes in the response of the lamb ductus arteriosus to oxygen and ibuprofen. Can J Physiol Pharmacol 1979; 57: 825–31

    Article  PubMed  CAS  Google Scholar 

  77. Chemtob S, Beharry K, Rex J, et al. Prostanoids determine the range of cerebral blood flow autoregulation of newborn piglets. Stroke 1990; 21: 777–84

    Article  PubMed  CAS  Google Scholar 

  78. Chemtob S, Beharry K, Barna T, et al. Differences in the effects in the newborn piglet of various nonsteroidal antiinflammatory drugs on cerebral blood flow but not on cerebrovascular prostaglandins. Pediatr Res 1991; 30: 106–11

    Article  PubMed  CAS  Google Scholar 

  79. Malcom DD, Segar JL, Robillard E, et al. Indomethacin compromises hemodynamics during positive-pressure ventilation, independently of prostanoids. J Appl Physiol 1993; 74: 1672–8

    Google Scholar 

  80. Chemtob S, Roy MS, Abran D, et al. Prevention of postasphyxial increase in lipid peroxides and retinal function deterioration in the newborn pig by inhibition of cyclooxygenase activity and free radical generation. Pediatr Res 1993; 33: 336–40

    PubMed  CAS  Google Scholar 

  81. Aranda JV, Varvarigou N, Beharry K, et al. The effect of early intravenous ibuprofen on renal function in premature newborns [abstract]. Pediatr Res 1994; 37: 361A

    Google Scholar 

  82. Gupta P. Ibuprofen vs indomethacin for treatment of PDA in preterm infants. Indian Pediatr 1998; 35(3): 292–3

    PubMed  CAS  Google Scholar 

  83. McIntire SC, Rubenstein RC, Gartner JC, et al. Acute flank pain and reversible renal dysfunction associated with nonsteroidal antiinflammatory drug use. Pediatrics 1993; 92: 459–60

    PubMed  CAS  Google Scholar 

  84. Wattad A, Feehan T, Shepard FM, et al. A unique complication of nonsteroidal antiinflammatory drug use [letter]. Pediatrics 1994; 93: 693

    PubMed  CAS  Google Scholar 

  85. Lesko SM, Mitchell AA. Renal function after short term ibuprofen use in infants and children. Pediatrics 1997; 100(6): 954–7

    Article  PubMed  CAS  Google Scholar 

  86. Slone D, Shapiro S, Miettinen OS, et al. Drug evaluation after marketing: a policy perspective. Ann Intern Med 1979; 90: 257–61

    PubMed  CAS  Google Scholar 

  87. Mitchell AA, Lesko SM. When a randomized controlled trial is needed to assess drug safety: the case of pediatric ibuprofen. Drug Saf 1995; 13: 15–24

    Article  PubMed  CAS  Google Scholar 

  88. Al-Harbi NN, Domrongkitchaiporn S, Lirenman DS. Hypocalcemia and hypomagnesemia after ibuprofen overdose. Ann Pharmacother 1997; 31: 432–4

    PubMed  CAS  Google Scholar 

  89. Kelley MT, Walson PD, Hayes JR, et al. Safety of paracetamol and ibuprofen in febrile children. Drug Invest 1993; 6: 48–55

    Article  Google Scholar 

  90. Kim J, Gazarian M, Verjee Z, et al. Acute renal insufficiency in ibuprofen overdose. Pediatr Emerg Care 1995; 11: 107–8

    Article  PubMed  CAS  Google Scholar 

  91. Kovesi TA, Swartz R, MacDonald N. Transient renal failure due to simultaneous ibuprofen and aminoglycoside therapy in children with cystic fibrosis. N Engl J Med 1998; 338(1): 65–6

    Article  PubMed  CAS  Google Scholar 

  92. Lesk SM, Mitchell AA. An assessment of the safety of pediatric ibuprofen: a practitioner-based randomized clinical trial. JAMA 1995; 273: 929–33

    Article  Google Scholar 

  93. Moghal NE, Hulton SA, Milford DV. Care in the use of ibuprofen as an antipyretic in children. Clin Nephrol 1998; 49(5): 293–5

    PubMed  CAS  Google Scholar 

  94. Schaller S, Kaplan BS. Acute nonoliguric renal failure in children associated with nonsteroidal antiinflammatory agents. Pediatr Emerg Care 1998; 14(6): 416–8

    Article  PubMed  CAS  Google Scholar 

  95. Simckes AM, Chen SS, Osorio AV, et al. Ketorolac-induced irreversible renal failure in sickle cell disease: a case report. Pediatr Nephrol 1999; 13: 63–7

    Article  PubMed  CAS  Google Scholar 

  96. Van Biljou G. Reversible renal failure associated with ibuprofen in a child: a case report. S Afr Med J 1989; 76: 34–5

    Google Scholar 

  97. Fanos V, Cataldi L. Antibacterial-induced nephrotoxicity in the newborn. Drug Saf 1999; 20(3): 245–67

    Article  PubMed  CAS  Google Scholar 

  98. Vane JR, Botting RM. Mechanisms of action of anti-inflammatory drugs. In: Vane JR, Botting RM, Botting G editors. Improved non-steroid anti-inflammatory drugs: COX-2 enzyme inhibitors.Dordrecht: Kluwer Academic, 1996: 1–27

    Chapter  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Vassilios Fanos.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Cuzzolin, L., Dal Cerè, M. & Fanos, V. NSAID-Induced Nephrotoxicity from the Fetus to the Child. Drug-Safety 24, 9–18 (2001). https://doi.org/10.2165/00002018-200124010-00002

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00002018-200124010-00002

Keywords

Navigation